Patients on nifurtimox for Chagas disease frequently report adverse events, mostly mild

Most patients who received nifurtimox for the treatment of Chagas disease during a 20-year CDC-sponsored program reported adverse events, according to a study published Thursday in MMWR.
Although most of the reported adverse events were mild in nature, the authors of the new report said health care providers “should be aware of the frequency and profile of adverse events when counseling patients and prescribing nifurtimox” as it becomes more widely available under a recent FDA approval.
Andrew Abbott, MD, an Epidemic Intelligence Service officer in the CDC’s Division of

Most patients who received nifurtimox for the treatment of Chagas disease during a 20-year CDC-sponsored program reported adverse events, according to a study published Thursday in MMWR.
Although most of the reported adverse events were mild in nature, the authors of the new report said health care providers “should be aware of the frequency and profile of adverse events when counseling patients and prescribing nifurtimox” as it becomes more widely available under a recent FDA approval.
Andrew Abbott, MD, an Epidemic Intelligence Service officer in the CDC’s Division of